Ichnos Sciences News Today

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Glenmark Pharmaceuticals Ltd , a leading, research-driven, global pharmaceutical company, and Ichnos Sciences...

IGI is introducing a pipeline of three oncology molecules currently undergoing clinical trials, targeting multiple myeloma, acute myeloid leukemia, and solid tumors.

Stocks to watch out for today: IRCON International, Maruti Suzuki, Infosys, HCL Tech, RITES, Paytm, Persistent Systems, IDBI Bank, Glenmark Pharmaceuticals, HDFC Asset Management Company, Sun Pharma, Advance Lifestyles and more

With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the companys prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.

-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis –-- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company f...

Glenmark subsidiary Ichnos will receive up to $320 million in upfront, development, regulatory and sales milestone payments in addition to up to low double-digit royalties

By Ben Glickman Astria Therapeutics entered a global exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential...

By Ben Glickman Shares of Astria Therapeutics rose after the company secured a licensing deal for a potential treatment of atopic dermatitis. The stock was...

/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today...